<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Korean J Anesthesiol</journal-id><journal-id journal-id-type="iso-abbrev">Korean J Anesthesiol</journal-id><journal-id journal-id-type="publisher-id">KJAE</journal-id><journal-title-group><journal-title>Korean Journal of Anesthesiology</journal-title></journal-title-group><issn pub-type="ppub">2005-6419</issn><issn pub-type="epub">2005-7563</issn><publisher><publisher-name>The Korean Society of Anesthesiologists</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26045930</article-id><article-id pub-id-type="pmc">4452671</article-id><article-id pub-id-type="doi">10.4097/kjae.2015.68.3.267</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Research Article</subject></subj-group></article-categories><title-group><article-title>The effect of combination treatment using palonosetron and dexamethasone for the prevention of postoperative nausea and vomiting versus dexamethasone alone in women receiving intravenous patient-controlled analgesia</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ryoo</surname><given-names>Seung-hwa</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Yoo</surname><given-names>Jae Hwa</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Mun Gyu</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Ki Hoon</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Kim</surname><given-names>Soon Im</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Anesthesiology and Pain Medicine, KR Clinic, Wonju, Korea.</aff><aff id="A2"><label>2</label>Department of Anesthesiology and Pain Medicine, Soonchunhyang University Hospital Seoul, Seoul, Korea.</aff><author-notes><corresp>Corresponding author: Soon Im Kim, M.D., Ph.D. Department of Anesthesiology and Pain Medicine, Soonchunhyang University Hospital Seoul, 59, Daesagwan-ro, Yongsan-gu, Seoul 140-743, Korea. Tel: 82-2-790-9294, Fax: 82-2-790-0394, <email>soonnim@schmc.ac.kr</email></corresp></author-notes><pub-date pub-type="ppub"><month>6</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>28</day><month>5</month><year>2015</year></pub-date><volume>68</volume><issue>3</issue><fpage>267</fpage><lpage>273</lpage><history><date date-type="received"><day>13</day><month>10</month><year>2014</year></date><date date-type="rev-recd"><day>26</day><month>11</month><year>2014</year></date><date date-type="accepted"><day>17</day><month>12</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; the Korean Society of Anesthesiologists, 2015</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Background</title><p>The purpose of this study was to evaluate the effect of palonosetron combined with dexamethasone for the prevention of PONV compared to dexamethasone alone in women who received intravenous patient-controlled analgesia (IV-PCA) using fentanyl.</p></sec><sec><title>Methods</title><p>In this randomized, double-blinded, placebo-controlled study, 204 healthy female patients who were scheduled to undergo elective surgery under general anesthesia followed by IV-PCA for postoperative pain control were enrolled. Patients were divided into two groups: the PD group (palonosetron 0.075 mg and dexamethasone 5 mg IV; n = 102) and the D group (dexamethasone 5 mg IV; n = 102). The treatments were given after the induction of anesthesia. The incidence of nausea, vomiting, severity of nausea, and the use of rescue anti-emetics during the first 48 hours after surgery were evaluated.</p></sec><sec><title>Results</title><p>The incidence of PONV was significantly lower in the PD group compared with the D group during the 0-24 hours (43 vs. 59%) and 0-48 hours after surgery (45 vs. 63%) (P &#x0003c; 0.05). The severity of nausea during the 6-24 hours after surgery was significantly less in the PD group compared with the D group (P &#x0003c; 0.05). The incidence of rescue antiemetic used was significantly lower in the PD group than in the D group during the 0-6 hours after surgery (13.1 vs. 24.5%) (P &#x0003c; 0.05).</p></sec><sec><title>Conclusions</title><p>Palonosetron combined with dexamethasone was more effective in preventing PONV compared to dexamethasone alone in women receiving IV-PCA using fentanyl.</p></sec></abstract><kwd-group><kwd>Dexamethasone</kwd><kwd>Palonosetron</kwd><kwd>Postoperative nausea and vomiting</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Postoperative nausea and vomiting (PONV) is one of the most common distressing complications after anesthesia and surgery. Serotonin 5-hydroxytryptamine type 3 (5-HT<sub>3</sub>) receptor antagonists are widely used as one of the first-line therapeutic agent for the prevention of PONV because of their good efficacy and minimal side effects [<xref rid="B1" ref-type="bibr">1</xref>].</p><p>Palonosetron, the latest 5-HT<sub>3</sub> receptor antagonist, has a higher receptor binding affinity and a longer plasma half-life than older 5-HT<sub>3</sub> receptor antagonist such as ondansetron, granisetron, dolasetron, and ramosetron. In contrast to the older 5-HT<sub>3</sub> receptor antagonists, palonosetron's allosteric binding and positive cooperativity triggers receptor internalization, which result in persistent inhibition of 5-HT<sub>3</sub> receptor function and long duration of action [<xref rid="B2" ref-type="bibr">2</xref>]. It was reported that palonosetron was more effective than ondansetron in preventing chemotherapy-induced nausea and vomiting (CINV) [<xref rid="B3" ref-type="bibr">3</xref>], and PONV [<xref rid="B4" ref-type="bibr">4</xref>].</p><p>Patient-controlled analgesia (PCA) using opioid is widely used for postoperative pain control. Although safe and effective for controlling postoperative pain, PCA is associated with high incidence of PONV. Infrequently, severe PONV may be perceived as a failure of PCA for pain control, and patients may refuse to continue PCA treatment due to dissatisfaction [<xref rid="B5" ref-type="bibr">5</xref>].</p><p>It is recommended that patients at high risk of developing PONV receive a combination of two or more different classes of antiemetic agents rather than a single one, because none of the available antiemetic is entirely effective in preventing PONV [<xref rid="B6" ref-type="bibr">6</xref>].</p><p>One of the commonly used combinations for preventing PONV is a 5-HT<sub>3</sub> receptor antagonist with dexamethasone. It has been demonstrated that combining a 5-HT<sub>3</sub> receptor antagonist (ondansetron or ramosetron) with dexamethasone is more effective in preventing PONV than ondansetron, ramosetron or dexamethasone alone [<xref rid="B7" ref-type="bibr">7</xref>,<xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B10" ref-type="bibr">10</xref>].</p><p>Recently, however, it was reported that the combination of palonosetron and dexamethasone is no more effective than palonosetron alone for the prevention of PONV [<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B12" ref-type="bibr">12</xref>].</p><p>Additionally, the effect of palonosetron and dexamethasone combination in patients at high-risk for PONV who received intravenous patient-controlled analgesia (IV-PCA) using fentanyl for postoperative pain control has not yet been reported.</p><p>The aim of this study was to determine whether combination therapy using palonosetron and dexamethsone was more effective in preventing PONV than monotherapy with dexamethasone in women who received IV-PCA using fentanyl for postoperative pain control.</p></sec><sec sec-type="materials|methods"><title>Materials and Methods</title><p>Institutional Review Board approval was obtained prior to starting the research. After receiving written informed consent, 204 healthy female patients, aged 20-70 years with American Society of Anesthesiologists physical status of 1-2, who were scheduled for elective surgery under general anesthesia and wanted to receive IV-PCA for postoperative pain control, were included in our randomized, placebo-controlled, double-blinded study.</p><p>Exclusion criteria included pregnancy, body weight more than 30% above the ideal body weight, vomiting or retching within 24 hours before the operation, administration of antiemetics, steroids or psychoactive medications within 24 hours before the operation.</p><p>Patients were randomly allocated to one of the two groups according to a computer-generated random number table: 1) PD group, 0.075 mg of palonosetron plus 5 mg of dexamethasone IV; 2) D group, 5 mg of dexamethasone with normal saline IV. Study medications were administered immediately after the induction of anesthesia. The patients and the investigator who collected the postoperative data were blinded to the randomization.</p><p>A standardized anesthesia regimen was followed. All patients received midazolam 3-5 mg IM as premedication 30 min before surgery. General anesthesia was induced with propofol 2 mg/kg and fentanyl 2 &#x000b5;g/kg. Rocuronium 0.6 mg/kg was administered to facilitate endotracheal intubation. Anesthesia was maintained with desflurane or sevoflurane and nitrous oxide in oxygen (50%). At the end of surgery, residual neuromuscular block was reversed with pyridostigmine and glycopyrrolate. For postoperative pain control, patients were given fentanyl using IV-PCA (bolus dose 15 ug fentanyl with background infusion [15 ug fentanyl/h], lockout interval of 6 minutes). After surgery, patients were observed in the postanesthetic care unit (PACU) for 1 hour, and then transferred to the ward.</p><p>The incidence of nausea and vomiting, severity of nausea, and use of rescue antiemetic were evaluated at 1 hour after the surgery while in the PACU, then at 6, 24 and 48 hours after the surgery while at the ward. Evaluation was made by the investigator blinded to the treatment. An episode of vomiting was defined as either vomiting (expulsion of stomach contents) or retching (an involuntary attempt to vomit but not productive of stomach contents). The severity of nausea was assessed using a four point verbal rating scale (none, mild, moderate, and severe). Rescue medication for PONV (metoclopramide 10 mg as an initial rescue drug, ondansetron 4 mg as a second rescue drug) was administered upon the patient's request, or upon complaint of moderate to severe nausea or vomiting. For inadequate pain control in spite of sufficient use of IV-PCA, additional analgesic medications were allowed at the discretion of the surgeon. The pain intensity was not assessed in this study.</p><p>Adverse events were evaluated and recorded during the entire observation period. Patients were also asked to rate their overall satisfaction with the anesthetic experience on a three point scale (satisfied; neutral; dissatisfied) at 48 hours postoperatively.</p><p>The primary outcome measured in this study was the incidence of PONV during the 0-24 hours postoperative period, and the secondary outcome measured were the incidence of PONV during the 24-48 hours postoperative period, 0-48 hours postoperative period, the severity of nausea, the use of rescue antiemetics and patient's satisfaction.</p><p>The sample size was calculated based on the incidence of PONV (approximately 60%) among patients receiving dexamethasone alone for antiemetic prophylaxis while on IV-PCA [<xref rid="B7" ref-type="bibr">7</xref>]. A risk reduction from 60 to 40% in the incidence of PONV by palonosetron combined with dexamethasone would be clinically relevant [<xref rid="B13" ref-type="bibr">13</xref>]. For a two-sided test of difference, using &#x003b1; = 0.05 and &#x003b2; = 0.2, the sample size was estimated at 97 patients per group. We enrolled 102 patients per group to allow for possible patient dropout.</p><p>Statistical analysis was performed using SPSS for Windows (version 14, SPSS Inc., Chicago, IL, USA). The student's t-test was used to compare the continuous variables between the groups. Categorical variables were analyzed using the &#x003c7;<sup>2</sup> test or Fisher's exact test, as appropriate. A P value of &#x0003c; 0.05 was considered statistically significant. Data are presented as means &#x000b1; standard deviation (SD), numbers, or percentages.</p></sec><sec sec-type="results"><title>Results</title><p>Among the 204 patients enrolled in this study, 11 were withdrawn from the study for insufficient data collection due to them being discharged before 48 hours after the operation. Data obtained from the remaining 193 patients were analyzed, with 94 patients in the D group and 99 patients in the PD group.</p><p>There were no significant differences between the groups with respect to patient characteristics, motion sickness, previous PONV history, smoking status, duration of surgery, duration of anesthesia, and type of surgery (<xref ref-type="table" rid="T1">Table 1</xref>).</p><p>The incidence of PONV was significantly lower in the PD group than in the D group during the 0-24 hours (43 vs. 59%) (P = 0.036), and the 0-48 hours postoperative period (45 vs. 63%) (P = 0.016) (<xref ref-type="table" rid="T2">Table 2</xref>).</p><p>The severity of nausea during the 6-24 hours postoperative period was significantly less in the PD groups compared with the D group (P = 0.010) (<xref ref-type="table" rid="T3">Table 3</xref>).</p><p>The incidence of rescue antiemetic used was significantly lower in the PD group than in the D group during the 0-6 hours after the operation (13 vs. 24%) (P = 0.043) (<xref ref-type="table" rid="T2">Table 2</xref>).</p><p>There were no significant differences in the patient's satisfaction rating between the groups (<xref ref-type="table" rid="T4">Table 4</xref>).</p><p>Headache occurred more frequently in the PD group than the D group, but it was not statistically significant (P = 0.067) (<xref ref-type="table" rid="T4">Table 4</xref>).</p></sec><sec sec-type="discussion"><title>Discussion</title><p>In this study, the combination of palonosetron 0.075 mg and dexamethasone 5 mg was significantly more effective in preventing PONV than dexamethasone 5 mg alone during the first 48 hours after surgery in women who received IV-PCA using fentanyl for postoperative pain control.</p><p>Although the exact etiology of PONV is not well known, many factors may be involved; which include age, gender, obesity, anxiety, prior history of motion sickness or PONV, nonsmoking state, anesthetics, type of surgery, duration of surgery and anesthesia, use of opioids, postoperative ambulation, dizziness, postoperative pain, and oral intake [<xref rid="B14" ref-type="bibr">14</xref>].</p><p>Apfel et al. [<xref rid="B15" ref-type="bibr">15</xref>] reported four important independent risk factors that can be used to predict PONV: female gender, history of motion sickness or PONV, non-smoking, and the use of postoperative opioids. Based on these four risk factors, a simplified risk score for predicting PONV was developed. If none, 1, 2, 3, or 4 of these four risk factors are present, the incidence of PONV is approximately 10, 20, 40, 60 and 80%, respectively.</p><p>In this study, the patients were at high risk for PONV with 3 or 4 Apfel's risk factors for PONV. The patient characteristics and Apfel's risk factors were similar between the two groups. Therefore, the observed differences of the results were due to the treatment provided.</p><p>Many antiemetic agents such as dopamine receptor antagonists, serotonin 5-HT<sub>3</sub> receptor antagonists, histamine receptor antagonists, cholinergic receptor antagonists, NK 1 receptor antagonists, and dexamethasone are already available [<xref rid="B1" ref-type="bibr">1</xref>].</p><p>The serotonin 5-HT<sub>3</sub> receptor antagonists, such as ondansetron, tropisetron, granisetron, dolasetron, and ramosetron, exert their antiemetic effect via competitive binding at the 5-HT<sub>3</sub> receptor sites which antagonize the effect of serotonin (5-HT), centrally and peripherally [<xref rid="B6" ref-type="bibr">6</xref>]. Palonosetron, the latest 5-HT<sub>3</sub> receptor antagonist, has a stronger binding affinity and longer plasma half-life (exceeding 40 h) than the older 5-HT<sub>3</sub> receptor antagonists (5-12 h) which results in prolonged inhibition of receptor function. In addition, palonosetron has significantly different characteristics from the older 5-HT<sub>3</sub> receptor antagonists. First, palonosetron differs in chemical structure compared to the older 5-HT<sub>3</sub> receptor antagonists. The older drugs are based on a 3-substituted indole structure resembling serotonin, while palonosetron is based on a fused tricyclic ring system attached to a quinuclidine moiety. Second, palonosetron interacts with 5-HT<sub>3</sub> receptors very differently. Palonosetron exhibits allosteric binding and positive cooperativity when binding to the 5-HT<sub>3</sub> receptor, and triggers a receptor internalization resulting in prolonged inhibition of receptor function, whereas older 5-HT<sub>3</sub> receptors antagonists exhibits simple bimolecular competitive binding at the 5-HT<sub>3</sub> receptor [<xref rid="B16" ref-type="bibr">16</xref>].</p><p>Kovac et al. [<xref rid="B13" ref-type="bibr">13</xref>] showed that palonosetron 0.075 mg effectively reduced PONV up to 72 hours after an operation compared to placebo. During the first 24 hours after surgery, palonosetron 0.075 mg reduced the incidence of nausea (from 71 to 50%) and vomiting (from 60 to 40%) compared to placebo which correspond to a relative risk reduction of nausea by 31%, and relative risk reduction of vomiting by 34% [<xref rid="B13" ref-type="bibr">13</xref>]. In addition, palonosetron 0.075 mg was more effective than ondansetron 4 mg and ramosetron 0.3 mg in the prevention of PONV during the first 48 hours after laparoscopic surgery in high risk women receiving fentanyl-based IV-PCA [<xref rid="B17" ref-type="bibr">17</xref>]. Moon et al. [<xref rid="B4" ref-type="bibr">4</xref>] also reported that palonosetron was more effective in preventing PONV than ondansetron during 24 hours after surgery (42 vs. 62%). In a dose-ranging study compared with placebo, palonosetron 0.075 mg IV was found to be the effective dose for preventing PONV up to 24 hours after surgery [<xref rid="B13" ref-type="bibr">13</xref>]. Therefore, we used palonosetron 0.075 mg IV in this study.</p><p>Dexamethasone is an inexpensive, effective and safe antiemetic. Although the exact mechanism for dexamethasone's antiemetic effect is not well known, dexamethasone may exert central antiemetic actions mainly through activation of the glucocorticoid receptors in the nucleus of the solitary tract, the nucleus of raphe, and the area postrema [<xref rid="B18" ref-type="bibr">18</xref>]. Dexamethasone is widely used for CINV and PONV. Additionally, dexamethasone can prevent nausea and vomiting associated with intravenous or epidural opioid for postoperative pain control [<xref rid="B18" ref-type="bibr">18</xref>,<xref rid="B19" ref-type="bibr">19</xref>,<xref rid="B20" ref-type="bibr">20</xref>,<xref rid="B21" ref-type="bibr">21</xref>]. Lee et al. [<xref rid="B19" ref-type="bibr">19</xref>] reported that dexamethasone 8 mg IV reduced PONV significantly from 57% (placebo group) to 28% during the first 24 hours after surgery in patients receiving morphine IV-PCA for pain control. A meta-analysis to assess the efficacy of dexamethasone in reducing PONV showed that a single IV dose of dexamethasone 5 to 10 mg was effective in reducing PONV in women receiving neuraxial morphine for cesarean delivery or abdominal hysterectomy [<xref rid="B21" ref-type="bibr">21</xref>]. Additionally, the Society for Ambulatory Anesthesia guidelines recommended 4-5 mg dexamethasone IV for prevention of PONV [<xref rid="B22" ref-type="bibr">22</xref>]. Dexamethasone 5 mg IV was chosen in this study and was administered in all patients who received IV-PCA using fentanyl for postoperative pain control.</p><p>Even though new antiemetic drugs have been introduced, there are no agents that can completely prevent or treat PONV because of the multifactorial etiology and various receptor sites involved in PONV. Therefore, in patients at high risk for PONV, it is recommended that combination therapy using several antiemetics targeting different receptor sites be employed rather than using a single antiemetic agent [<xref rid="B6" ref-type="bibr">6</xref>]. It was reported that combination therapy using a 5-HT<sub>3</sub> receptor antagonist with either droperidol or dexamethasone, and droperidol with dexamethasone were more effective than therapy using a single antiemetic agent [<xref rid="B23" ref-type="bibr">23</xref>,<xref rid="B24" ref-type="bibr">24</xref>,<xref rid="B25" ref-type="bibr">25</xref>].</p><p>Combination therapy using a 5-HT<sub>3</sub> receptor antagonist with dexamethasone became widely used after the issuance of a Food and Drug Administration black box warning on droperidol. A number of studies have reported that combination therapy using the older 5-HT<sub>3</sub> receptor antagonists such as ondansetron, tropisetron, or ramosetron with dexamethasone were more effective in reducing PONV than monotherapy [<xref rid="B7" ref-type="bibr">7</xref>,<xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B10" ref-type="bibr">10</xref>,<xref rid="B26" ref-type="bibr">26</xref>,<xref rid="B27" ref-type="bibr">27</xref>]. The authors thought that the combination of palonosetron and dexamethasone may reduce PONV more effectively than monotherapy using either palonosetron or dexamethasone, similar to the effect offered by combination of the older 5-HT<sub>3</sub> receptor antagonists and dexamethasone.</p><p>However, there were two published studies claiming that combination therapy using palonosetron with dexamethasone did not reduce the incidence of PONV compared to palonosetron alone [<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B12" ref-type="bibr">12</xref>]. A study by Blitz et al. [<xref rid="B11" ref-type="bibr">11</xref>], involving elective outpatient laparoscopic abdominal or gynecological surgery with subjects having at least 3 Apfel's risk factors for PONV, showed that the combination of palonosetron 0.075 mg and dexamethsone 8 mg did not significantly reduce the incidence of PONV compared to using palonosetron 0.075 mg alone during the first 72 hours postoperative period (postoperative 0-2 h: 19 vs. 16%, 0-6 h: 44 vs. 42%, 6-72 h: 42 vs. 28%, palonosetron vs. palonosetron plus dexamethasone respectively) [<xref rid="B11" ref-type="bibr">11</xref>]. A study by Park et al. [<xref rid="B12" ref-type="bibr">12</xref>] showed that the combination of palonosetron 0.075 mg with dexamethasone 4 mg did not reduce the incidence of PONV in patients with at least 2 risk factors for PONV during the 24 hours after operation compared to palonosetron 0.075 mg alone (14 vs. 9.8%) [<xref rid="B12" ref-type="bibr">12</xref>].</p><p>It is unknown whether palonosetron, when used in combination with dexamethasone, acted differently in contrast to the older 5-HT<sub>3</sub> receptor antagonists because of palonosetron's different chemical structure and different interaction with the 5-HT<sub>3</sub> receptors. Therefore, this study was conducted to determine whether combination therapy using palonosetron and dexamethsone was more effective in preventing PONV than monotherapy with dexamethasone.</p><p>The result of our study demonstrated that combination therapy using palonosetron 0.075 mg and dexamethsone 5 mg was more effective in preventing PONV than monotherapy with dexamethsone 5 mg. This result was comparable to the results of previous studies claiming that combination of dexamethasone plus ondansetron is more effective in preventing PONV than dexamethasone alone [<xref rid="B7" ref-type="bibr">7</xref>,<xref rid="B10" ref-type="bibr">10</xref>]. A study by Wang et al. [<xref rid="B7" ref-type="bibr">7</xref>] showed that ondansetron 4 mg with dexamethasone 5 mg significantly reduced PONV compared to dexamethasone 5 mg alone in women receiving postoperative morphine PCA (30 vs. 57%) in the first 24 hours after surgery [<xref rid="B7" ref-type="bibr">7</xref>].</p><p>Apfel et al. [<xref rid="B28" ref-type="bibr">28</xref>] reported that dexamethasone 4 mg reduced PONV risk for 24 hours after an operation by about 26%, similar to ondansetron 4 mg or droperidol 1.25 mg. These antiemetic interventions were similarly effective and acted independently of one another and independently of the patients' baseline risk.</p><p>Base on the result of our study, it seems that palonosetron and dexamethasone also acted independently as did other older antiemetics [<xref rid="B28" ref-type="bibr">28</xref>].</p><p>More recently, Bala et al. [<xref rid="B29" ref-type="bibr">29</xref>] reported that combination of palonosetron 0.075 mg and dexamethasone 8 mg was more effective than palonosetron 0.075 mg alone in reducing PONV after laparoscopic cholecystectomy. Nausea occurred in 42.9% and vomiting occurred in 33.3% of patients who received palonosetron alone, while nausea occurred in 14.3% and vomiting occurred in 11.9% of patients who received combination of palonosetron and dexamethasone, during the first 24 hours after surgery. The requirement for rescue antiemetic was also significantly less in the combination treatment group than palonosetron alone group. This result is contrary to the results of studies by Blitz et al. [<xref rid="B11" ref-type="bibr">11</xref>] and Park et al. [<xref rid="B12" ref-type="bibr">12</xref>] It is believed that palonosetron and dexamethasone acted independently.</p><p>Accordingly, the combination of palonosetron and dexamethasone was beneficial in preventing PONV compared to dexamethasone alone in patients at high risk for PONV.</p><p>Headache, one of the side effects of 5-HT<sub>3</sub> receptor antagonist, occurred more frequently in patients who received palonosetron combined with dexamethasone than dexamethasone alone in this study, but the difference was not significant. Known adverse effects of dexamethasone such as wound infection and delayed wound healing should be watched out for, but a single perioperative dose of dexamethasone is considered to be relatively free of side effects [<xref rid="B30" ref-type="bibr">30</xref>]. The adverse effects of dexamethasone were not evaluated in this study.</p><p>A limitation of this study was the absence of a placebo group which is required for calculation of absolute risk reduction. Since it is unethical to withhold antiemetics in patients at high risk for PONV, a placebo group was not included.</p><p>In conclusion, the combination of palonosetron with dexamethasone was more effective in preventing PONV compared to dexamethasone alone in women receiving IV-PCA using fentanyl.</p></sec></body><back><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gan</surname><given-names>TJ</given-names></name><name><surname>Diemunsch</surname><given-names>P</given-names></name><name><surname>Habib</surname><given-names>AS</given-names></name><name><surname>Kovac</surname><given-names>A</given-names></name><name><surname>Kranke</surname><given-names>P</given-names></name><name><surname>Meyer</surname><given-names>TA</given-names></name><etal/></person-group><article-title>Consensus guidelines for the management of postoperative nausea and vomiting</article-title><source>Anesth Analg</source><year>2014</year><volume>118</volume><fpage>85</fpage><lpage>113</lpage><pub-id pub-id-type="pmid">24356162</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rojas</surname><given-names>C</given-names></name><name><surname>Thomas</surname><given-names>AG</given-names></name><name><surname>Alt</surname><given-names>J</given-names></name><name><surname>Stathis</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Rubenstein</surname><given-names>EB</given-names></name><etal/></person-group><article-title>Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function</article-title><source>Eur J Pharmacol</source><year>2010</year><volume>626</volume><fpage>193</fpage><lpage>199</lpage><pub-id pub-id-type="pmid">19836386</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gralla</surname><given-names>R</given-names></name><name><surname>Lichinitser</surname><given-names>M</given-names></name><name><surname>Van Der Vegt</surname><given-names>S</given-names></name><name><surname>Sleeboom</surname><given-names>H</given-names></name><name><surname>Mezger</surname><given-names>J</given-names></name><name><surname>Peschel</surname><given-names>C</given-names></name><etal/></person-group><article-title>Palonosetron improves prevention of chemotherapyinduced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron</article-title><source>Ann Oncol</source><year>2003</year><volume>14</volume><fpage>1570</fpage><lpage>1577</lpage><pub-id pub-id-type="pmid">14504060</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moon</surname><given-names>YE</given-names></name><name><surname>Joo</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>JE</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name></person-group><article-title>Anti-emetic effect of ondansetron and palonosetron in thyroidectomy: a prospective, randomized, doubleblind study</article-title><source>Br J Anaesth</source><year>2012</year><volume>108</volume><fpage>417</fpage><lpage>422</lpage><pub-id pub-id-type="pmid">22277663</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tramer</surname><given-names>MR</given-names></name><name><surname>Walder</surname><given-names>B</given-names></name></person-group><article-title>Efficacy and adverse effects of prophylactic antiemetics during patient-controlled analgesia therapy: a quantitative systematic review</article-title><source>Anesth Analg</source><year>1999</year><volume>88</volume><fpage>1354</fpage><lpage>1361</lpage><pub-id pub-id-type="pmid">10357345</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Habib</surname><given-names>AS</given-names></name><name><surname>Gan</surname><given-names>TJ</given-names></name></person-group><article-title>Evidence-based management of postoperative nausea and vomiting: a review</article-title><source>Can J Anaesth</source><year>2004</year><volume>51</volume><fpage>326</fpage><lpage>341</lpage><pub-id pub-id-type="pmid">15064261</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>PK</given-names></name><name><surname>Tsay</surname><given-names>PJ</given-names></name><name><surname>Huang</surname><given-names>CC</given-names></name><name><surname>Lai</surname><given-names>HY</given-names></name><name><surname>Lin</surname><given-names>PC</given-names></name><name><surname>Huang</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Comparison of dexamethasone with ondansetron or haloperidol for prevention of patient-controlled analgesia-related postoperative nausea and vomiting: a randomized clinical trial</article-title><source>World J Surg</source><year>2012</year><volume>36</volume><fpage>775</fpage><lpage>781</lpage><pub-id pub-id-type="pmid">22297625</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>JW</given-names></name><name><surname>Park</surname><given-names>EY</given-names></name><name><surname>Lee</surname><given-names>JG</given-names></name><name><surname>Park</surname><given-names>YS</given-names></name><name><surname>Kang</surname><given-names>BC</given-names></name><name><surname>Shim</surname><given-names>YH</given-names></name></person-group><article-title>The effect of combining dexamethasone with ondansetron for nausea and vomiting associated with fentanyl-based intravenous patient-controlled analgesia</article-title><source>Anaesthesia</source><year>2011</year><volume>66</volume><fpage>263</fpage><lpage>267</lpage><pub-id pub-id-type="pmid">21401538</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>SY</given-names></name><name><surname>Jun</surname><given-names>NH</given-names></name><name><surname>Choi</surname><given-names>YS</given-names></name><name><surname>Kim</surname><given-names>JC</given-names></name><name><surname>Shim</surname><given-names>JK</given-names></name><name><surname>Ha</surname><given-names>SH</given-names></name><etal/></person-group><article-title>Efficacy of dexamethasone added to ramosetron for preventing postoperative nausea and vomiting in highly susceptible patients following spine surgery</article-title><source>Korean J Anesthesiol</source><year>2012</year><volume>62</volume><fpage>260</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">22474554</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bano</surname><given-names>F</given-names></name><name><surname>Zafar</surname><given-names>S</given-names></name><name><surname>Aftab</surname><given-names>S</given-names></name><name><surname>Haider</surname><given-names>S</given-names></name></person-group><article-title>Dexamethasone plus ondansetron for prevention of postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy: a comparison with dexamethasone alone</article-title><source>J Coll Physicians Surg Pak</source><year>2008</year><volume>18</volume><fpage>265</fpage><lpage>269</lpage><pub-id pub-id-type="pmid">18541078</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blitz</surname><given-names>JD</given-names></name><name><surname>Haile</surname><given-names>M</given-names></name><name><surname>Kline</surname><given-names>R</given-names></name><name><surname>Franco</surname><given-names>L</given-names></name><name><surname>Didehvar</surname><given-names>S</given-names></name><name><surname>Pachter</surname><given-names>HL</given-names></name><etal/></person-group><article-title>A randomized double blind study to evaluate efficacy of palonosetron with dexamethasone versus palonosetron alone for prevention of postoperative and postdischarge nausea and vomiting in subjects undergoing laparoscopic surgeries with high emetogenic risk</article-title><source>Am J Ther</source><year>2012</year><volume>19</volume><fpage>324</fpage><lpage>329</lpage><pub-id pub-id-type="pmid">21519222</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>JW</given-names></name><name><surname>Jun</surname><given-names>JW</given-names></name><name><surname>Lim</surname><given-names>YH</given-names></name><name><surname>Lee</surname><given-names>SS</given-names></name><name><surname>Yoo</surname><given-names>BH</given-names></name><name><surname>Kim</surname><given-names>KM</given-names></name><etal/></person-group><article-title>The comparative study to evaluate the effect of palonosetron monotherapy versus palonosetron with dexamethasone combination therapy for prevention of postoperative nausea and vomiting</article-title><source>Korean J Anesthesiol</source><year>2012</year><volume>63</volume><fpage>334</fpage><lpage>339</lpage><pub-id pub-id-type="pmid">23115686</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kovac</surname><given-names>AL</given-names></name><name><surname>Eberhart</surname><given-names>L</given-names></name><name><surname>Kotarski</surname><given-names>J</given-names></name><name><surname>Clerici</surname><given-names>G</given-names></name><name><surname>Apfel</surname><given-names>C</given-names></name></person-group><article-title>A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo in preventing postoperative nausea and vomiting over a 72-hour period</article-title><source>Anesth Analg</source><year>2008</year><volume>107</volume><fpage>439</fpage><lpage>444</lpage><pub-id pub-id-type="pmid">18633021</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watcha</surname><given-names>MF</given-names></name><name><surname>White</surname><given-names>PF</given-names></name></person-group><article-title>Postoperative nausea and vomiting. Its etiology, treatment, and prevention</article-title><source>Anesthesiology</source><year>1992</year><volume>77</volume><fpage>162</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">1609990</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Apfel</surname><given-names>CC</given-names></name><name><surname>Laara</surname><given-names>E</given-names></name><name><surname>Koivuranta</surname><given-names>M</given-names></name><name><surname>Greim</surname><given-names>CA</given-names></name><name><surname>Roewer</surname><given-names>N</given-names></name></person-group><article-title>A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers</article-title><source>Anesthesiology</source><year>1999</year><volume>91</volume><fpage>693</fpage><lpage>700</lpage><pub-id pub-id-type="pmid">10485781</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rojas</surname><given-names>C</given-names></name><name><surname>Stathis</surname><given-names>M</given-names></name><name><surname>Thomas</surname><given-names>AG</given-names></name><name><surname>Massuda</surname><given-names>EB</given-names></name><name><surname>Alt</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor</article-title><source>Anesth Analg</source><year>2008</year><volume>107</volume><fpage>469</fpage><lpage>478</lpage><pub-id pub-id-type="pmid">18633025</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Hong</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>WO</given-names></name><name><surname>Kil</surname><given-names>HK</given-names></name><name><surname>Karm</surname><given-names>MH</given-names></name><name><surname>Hwang</surname><given-names>JH</given-names></name></person-group><article-title>Palonosetron has superior prophylactic antiemetic efficacy compared with ondansetron or ramosetron in high-risk patients undergoing laparoscopic surgery: a prospective, randomized, double-blinded study</article-title><source>Korean J Anesthesiol</source><year>2013</year><volume>64</volume><fpage>517</fpage><lpage>523</lpage><pub-id pub-id-type="pmid">23814652</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>JJ</given-names></name><name><surname>Ho</surname><given-names>ST</given-names></name><name><surname>Wong</surname><given-names>CS</given-names></name><name><surname>Tzeng</surname><given-names>JI</given-names></name><name><surname>Liu</surname><given-names>HS</given-names></name><name><surname>Ger</surname><given-names>LP</given-names></name></person-group><article-title>Dexamethasone prophylaxis of nausea and vomiting after epidural morphine for post-Cesarean analgesia</article-title><source>Can J Anaesth</source><year>2001</year><volume>48</volume><fpage>185</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">11220429</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Lai</surname><given-names>HY</given-names></name><name><surname>Lin</surname><given-names>PC</given-names></name><name><surname>Lin</surname><given-names>YS</given-names></name><name><surname>Huang</surname><given-names>SJ</given-names></name><name><surname>Shyr</surname><given-names>MH</given-names></name></person-group><article-title>A dose ranging study of dexamethasone for preventing patient-controlled analgesiarelated nausea and vomiting: a comparison of droperidol with saline</article-title><source>Anesth Analg</source><year>2004</year><volume>98</volume><fpage>1066</fpage><lpage>1071</lpage><pub-id pub-id-type="pmid">15041600</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tzeng</surname><given-names>JI</given-names></name><name><surname>Wang</surname><given-names>JJ</given-names></name><name><surname>Ho</surname><given-names>ST</given-names></name><name><surname>Tang</surname><given-names>CS</given-names></name><name><surname>Liu</surname><given-names>YC</given-names></name><name><surname>Lee</surname><given-names>SC</given-names></name></person-group><article-title>Dexamethasone for prophylaxis of nausea and vomiting after epidural morphine for post-Caesarean section analgesia: comparison of droperidol and saline</article-title><source>Br J Anaesth</source><year>2000</year><volume>85</volume><fpage>865</fpage><lpage>868</lpage><pub-id pub-id-type="pmid">11732521</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>TK</given-names></name><name><surname>Jones</surname><given-names>CA</given-names></name><name><surname>Habib</surname><given-names>AS</given-names></name></person-group><article-title>Dexamethasone for the prophylaxis of postoperative nausea and vomiting associated with neuraxial morphine administration: a systematic review and meta-analysis</article-title><source>Anesth Analg</source><year>2012</year><volume>114</volume><fpage>813</fpage><lpage>822</lpage><pub-id pub-id-type="pmid">22344239</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gan</surname><given-names>TJ</given-names></name><name><surname>Meyer</surname><given-names>TA</given-names></name><name><surname>Apfel</surname><given-names>CC</given-names></name><name><surname>Chung</surname><given-names>F</given-names></name><name><surname>Davis</surname><given-names>PJ</given-names></name><name><surname>Habib</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Society for Ambulatory Anesthesia guidelines for the management of postoperative nausea and vomiting</article-title><source>Anesth Analg</source><year>2007</year><volume>105</volume><fpage>1615</fpage><lpage>1628</lpage><pub-id pub-id-type="pmid">18042859</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>O</given-names></name><name><surname>Belo</surname><given-names>SE</given-names></name><name><surname>Koutsoukos</surname><given-names>G</given-names></name></person-group><article-title>Additive anti-emetic efficacy of prophylactic ondansetron with droperidol in out-patient gynecological laparoscopy</article-title><source>Can J Anaesth</source><year>2000</year><volume>47</volume><fpage>529</fpage><lpage>536</lpage><pub-id pub-id-type="pmid">10875716</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Habib</surname><given-names>AS</given-names></name><name><surname>El-Moalem</surname><given-names>HE</given-names></name><name><surname>Gan</surname><given-names>TJ</given-names></name></person-group><article-title>The efficacy of the 5-HT3 receptor antagonists combined with droperidol for PONV prophylaxis is similar to their combination with dexamethasone. A meta-analysis of randomized controlled trials</article-title><source>Can J Anaesth</source><year>2004</year><volume>51</volume><fpage>311</fpage><lpage>319</lpage><pub-id pub-id-type="pmid">15064259</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>JI</given-names></name><name><surname>Lo</surname><given-names>Y</given-names></name><name><surname>Chia</surname><given-names>YY</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Fong</surname><given-names>WP</given-names></name><name><surname>Yang</surname><given-names>LC</given-names></name><etal/></person-group><article-title>Prevention of postoperative nausea and vomiting after intrathecal morphine for Cesarean section: a randomized comparison of dexamethasone, droperidol, and a combination</article-title><source>Int J Obstet Anesth</source><year>2007</year><volume>16</volume><fpage>122</fpage><lpage>127</lpage><pub-id pub-id-type="pmid">17275282</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holt</surname><given-names>R</given-names></name><name><surname>Rask</surname><given-names>P</given-names></name><name><surname>Coulthard</surname><given-names>KP</given-names></name><name><surname>Sinclair</surname><given-names>M</given-names></name><name><surname>Roberts</surname><given-names>G</given-names></name><name><surname>Van Der Walt</surname><given-names>J</given-names></name><etal/></person-group><article-title>Tropisetron plus dexamethasone is more effective than tropisetron alone for the prevention of postoperative nausea and vomiting in children undergoing tonsillectomy</article-title><source>Paediatr Anaesth</source><year>2000</year><volume>10</volume><fpage>181</fpage><lpage>188</lpage><pub-id pub-id-type="pmid">10736082</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x000f3;pez-Olaondo</surname><given-names>L</given-names></name><name><surname>Carrascosa</surname><given-names>F</given-names></name><name><surname>Pueyo</surname><given-names>FJ</given-names></name><name><surname>Monedero</surname><given-names>P</given-names></name><name><surname>Busto</surname><given-names>N</given-names></name><name><surname>S&#x000e1;ez</surname><given-names>A</given-names></name></person-group><article-title>Combination of ondansetron and dexamethasone in the prophylaxis of postoperative nausea and vomiting</article-title><source>Br J Anaesth</source><year>1996</year><volume>76</volume><fpage>835</fpage><lpage>840</lpage><pub-id pub-id-type="pmid">8679359</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Apfel</surname><given-names>CC</given-names></name><name><surname>Korttila</surname><given-names>K</given-names></name><name><surname>Abdalla</surname><given-names>M</given-names></name><name><surname>Kerger</surname><given-names>H</given-names></name><name><surname>Turan</surname><given-names>A</given-names></name><name><surname>Vedder</surname><given-names>I</given-names></name><etal/></person-group><article-title>A factorial trial of six interventions for the prevention of postoperative nausea and vomiting</article-title><source>N Engl J Med</source><year>2004</year><volume>350</volume><fpage>2441</fpage><lpage>2451</lpage><pub-id pub-id-type="pmid">15190136</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bala</surname><given-names>I</given-names></name><name><surname>Bharti</surname><given-names>N</given-names></name><name><surname>Murugesan</surname><given-names>S</given-names></name><name><surname>Gupta</surname><given-names>R</given-names></name></person-group><article-title>Comparison of palonosetron with palonosetron-dexamethasone combination for prevention of postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy</article-title><source>Minerva Anestesiol</source><year>2014</year><volume>80</volume><fpage>779</fpage><lpage>784</lpage><pub-id pub-id-type="pmid">24280811</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waldron</surname><given-names>NH</given-names></name><name><surname>Jones</surname><given-names>CA</given-names></name><name><surname>Gan</surname><given-names>TJ</given-names></name><name><surname>Allen</surname><given-names>TK</given-names></name><name><surname>Habib</surname><given-names>AS</given-names></name></person-group><article-title>Impact of perioperative dexamethasone on postoperative analgesia and side-effects: systematic review and meta-analysis</article-title><source>Br J Anaesth</source><year>2013</year><volume>110</volume><fpage>191</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">23220857</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Demographic Data and Baseline Characteristics of Patients</title></caption><alternatives><graphic xlink:href="kjae-68-267-i001"/><table frame="hsides" rules="rows"><thead><tr><th valign="middle" align="center" rowspan="1" colspan="1"/><th valign="middle" align="center" rowspan="1" colspan="1">D group (n = 94)</th><th valign="middle" align="center" rowspan="1" colspan="1">PD group (n = 99)</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (yr)</td><td valign="top" align="center" rowspan="1" colspan="1">50.6 &#x000b1; 10.8</td><td valign="top" align="center" rowspan="1" colspan="1">51.6 &#x000b1; 12.2</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Body weight (kg)</td><td valign="top" align="center" rowspan="1" colspan="1">60.2 &#x000b1; 8.9</td><td valign="top" align="center" rowspan="1" colspan="1">59.8 &#x000b1; 9.6</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">History of PONV (n)</td><td valign="top" align="center" rowspan="1" colspan="1">7</td><td valign="top" align="center" rowspan="1" colspan="1">4</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">History of motion sickness (n)</td><td valign="top" align="center" rowspan="1" colspan="1">20</td><td valign="top" align="center" rowspan="1" colspan="1">25</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Non-smoker (n)</td><td valign="top" align="center" rowspan="1" colspan="1">92</td><td valign="top" align="center" rowspan="1" colspan="1">93</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Duration of surgery (min)</td><td valign="top" align="center" rowspan="1" colspan="1">119 &#x000b1; 80.3</td><td valign="top" align="center" rowspan="1" colspan="1">104 &#x000b1; 60.8</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Duration of anesthesia (min)</td><td valign="top" align="center" rowspan="1" colspan="1">168 &#x000b1; 84.7</td><td valign="top" align="center" rowspan="1" colspan="1">151 &#x000b1; 69.8</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Type of surgery (n)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;General</td><td valign="top" align="center" rowspan="1" colspan="1">20</td><td valign="top" align="center" rowspan="1" colspan="1">26</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Orthopedic</td><td valign="top" align="center" rowspan="1" colspan="1">66</td><td valign="top" align="center" rowspan="1" colspan="1">64</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Gynecological</td><td valign="top" align="center" rowspan="1" colspan="1">8</td><td valign="top" align="center" rowspan="1" colspan="1">9</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>Values are expressed as mean &#x000b1; SD, or number of patients (n). D group: 5 mg of dexamethasone with normal saline IV, PD group: 0.075 mg of palonosetron plus 5 mg of dexamethasone IV.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Incidence of Nausea and Vomiting, and Use of Rescue Antiemetics during the First 48 Hours after Surgery</title></caption><alternatives><graphic xlink:href="kjae-68-267-i002"/><table frame="hsides" rules="rows"><thead><tr><th valign="middle" align="center" rowspan="1" colspan="1"/><th valign="middle" align="center" rowspan="1" colspan="1">D group (n = 94)</th><th valign="middle" align="center" rowspan="1" colspan="1">PD group (n = 99)</th><th valign="middle" align="center" rowspan="1" colspan="1">P values</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">0-6 h</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" rowspan="1" colspan="1">&#x02003;Nausea</td><td valign="top" align="center" rowspan="1" colspan="1">43 (46%)</td><td valign="top" align="center" rowspan="1" colspan="1">38 (38%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.300</td></tr><tr><td valign="top" rowspan="1" colspan="1">&#x02003;Vomiting</td><td valign="top" align="center" rowspan="1" colspan="1">14 (15%)</td><td valign="top" align="center" rowspan="1" colspan="1">10 (10%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.313</td></tr><tr><td valign="top" rowspan="1" colspan="1">&#x02003;PONV</td><td valign="top" align="center" rowspan="1" colspan="1">43 (46%)</td><td valign="top" align="center" rowspan="1" colspan="1">38 (38%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.300</td></tr><tr><td valign="top" rowspan="1" colspan="1">&#x02003;Rescue antiemetics</td><td valign="top" align="center" rowspan="1" colspan="1">23 (24%)</td><td valign="top" align="center" rowspan="1" colspan="1">13 (13%)<sup>*</sup></td><td valign="top" align="center" rowspan="1" colspan="1">0.043</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">6-24 h</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Nausea</td><td valign="top" align="center" rowspan="1" colspan="1">30 (32%)</td><td valign="top" align="center" rowspan="1" colspan="1">20 (20%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.063</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Vomiting</td><td valign="top" align="center" rowspan="1" colspan="1">12 (13%)</td><td valign="top" align="center" rowspan="1" colspan="1">6 (6%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.109</td></tr><tr><td valign="top" rowspan="1" colspan="1">&#x02003;PONV</td><td valign="top" align="center" rowspan="1" colspan="1">30 (32%)</td><td valign="top" align="center" rowspan="1" colspan="1">21 (21%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.092</td></tr><tr><td valign="top" rowspan="1" colspan="1">&#x02003;Rescue antiemetics</td><td valign="top" align="center" rowspan="1" colspan="1">11 (12%)</td><td valign="top" align="center" rowspan="1" colspan="1">11 (11%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.897</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">0-24 h</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Nausea</td><td valign="top" align="center" rowspan="1" colspan="1">55 (59%)</td><td valign="top" align="center" rowspan="1" colspan="1">42 (42%)<sup>*</sup></td><td valign="top" align="center" rowspan="1" colspan="1">0.025</td></tr><tr><td valign="top" rowspan="1" colspan="1">&#x02003;Vomiting</td><td valign="top" align="center" rowspan="1" colspan="1">20 (21%)</td><td valign="top" align="center" rowspan="1" colspan="1">16 (16%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.362</td></tr><tr><td valign="top" rowspan="1" colspan="1">&#x02003;PONV</td><td valign="top" align="center" rowspan="1" colspan="1">55 (59%)</td><td valign="top" align="center" rowspan="1" colspan="1">43 (43%)<sup>*</sup></td><td valign="top" align="center" rowspan="1" colspan="1">0.036</td></tr><tr><td valign="top" rowspan="1" colspan="1">&#x02003;Rescue antiemetics</td><td valign="top" align="center" rowspan="1" colspan="1">29 (31%)</td><td valign="top" align="center" rowspan="1" colspan="1">21 (21%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.127</td></tr><tr><td valign="top" rowspan="1" colspan="1">24-48 h</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Nausea</td><td valign="middle" align="center" rowspan="1" colspan="1">22 (23%)</td><td valign="middle" align="center" rowspan="1" colspan="1">16 (16%)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.206</td></tr><tr><td valign="top" rowspan="1" colspan="1">&#x02003;Vomiting</td><td valign="top" align="center" rowspan="1" colspan="1">4 (4%)</td><td valign="top" align="center" rowspan="1" colspan="1">6 (6%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.572</td></tr><tr><td valign="top" rowspan="1" colspan="1">&#x02003;PONV</td><td valign="top" align="center" rowspan="1" colspan="1">22 (23%)</td><td valign="top" align="center" rowspan="1" colspan="1">17 (17%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.281</td></tr><tr><td valign="top" rowspan="1" colspan="1">&#x02003;Rescue antiemetics</td><td valign="top" align="center" rowspan="1" colspan="1">7 (7%)</td><td valign="top" align="center" rowspan="1" colspan="1">5 (5%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.491</td></tr><tr><td valign="top" rowspan="1" colspan="1">0-48 h</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" rowspan="1" colspan="1">&#x02003;Nausea</td><td valign="top" align="center" rowspan="1" colspan="1">59 (63%)</td><td valign="top" align="center" rowspan="1" colspan="1">44 (44%)<sup>*</sup></td><td valign="top" align="center" rowspan="1" colspan="1">0.011</td></tr><tr><td valign="top" rowspan="1" colspan="1">&#x02003;Vomiting</td><td valign="top" align="center" rowspan="1" colspan="1">23 (24%)</td><td valign="top" align="center" rowspan="1" colspan="1">18 (18%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.286</td></tr><tr><td valign="top" rowspan="1" colspan="1">&#x02003;PONV</td><td valign="top" align="center" rowspan="1" colspan="1">59 (63%)</td><td valign="top" align="center" rowspan="1" colspan="1">45 (45%)<sup>*</sup></td><td valign="top" align="center" rowspan="1" colspan="1">0.016</td></tr><tr><td valign="top" rowspan="1" colspan="1">&#x02003;Rescue antiemetics</td><td valign="top" align="center" rowspan="1" colspan="1">31 (33%)</td><td valign="top" align="center" rowspan="1" colspan="1">21 (21%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.066</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>Data are presented as number of patients (percentage). PONV: postoperative nausea and vomiting. D group: 5 mg of dexamethasone with normal saline IV, PD group: 0.075 mg of palonosetron plus 5 mg of dexamethasone IV. <sup>*</sup>P &#x0003c; 0.05.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><title>Severity of Nausea during the First 48 Hours after Surgery</title></caption><alternatives><graphic xlink:href="kjae-68-267-i003"/><table frame="hsides" rules="rows"><thead><tr><th valign="middle" align="center" rowspan="1" colspan="1"/><th valign="middle" align="center" rowspan="1" colspan="1">D group (n = 94)</th><th valign="middle" align="center" rowspan="1" colspan="1">PD group (n = 99)</th><th valign="middle" align="center" rowspan="1" colspan="1">P values</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">0-6 h</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;None</td><td valign="top" align="center" rowspan="1" colspan="1">51 (54%)</td><td valign="top" align="center" rowspan="1" colspan="1">61(62%)</td><td valign="top" align="center" rowspan="4" colspan="1">0.125</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Mild</td><td valign="top" align="center" rowspan="1" colspan="1">10 (11%)</td><td valign="top" align="center" rowspan="1" colspan="1">12 (12%)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Moderate</td><td valign="top" align="center" rowspan="1" colspan="1">6 (6%)</td><td valign="top" align="center" rowspan="1" colspan="1">9 (9%)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Severe</td><td valign="top" align="center" rowspan="1" colspan="1">27 (29%)</td><td valign="top" align="center" rowspan="1" colspan="1">17 (17%)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">6-24 h</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;None</td><td valign="top" align="center" rowspan="1" colspan="1">63(67%)</td><td valign="top" align="center" rowspan="1" colspan="1">79 (80%)</td><td valign="top" align="center" rowspan="4" colspan="1">0.010</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Mild</td><td valign="top" align="center" rowspan="1" colspan="1">9 (10%)</td><td valign="top" align="center" rowspan="1" colspan="1">10 (10%)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Moderate</td><td valign="top" align="center" rowspan="1" colspan="1">5 (5%)</td><td valign="top" align="center" rowspan="1" colspan="1">4 (4%))</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Severe</td><td valign="top" align="center" rowspan="1" colspan="1">17 (18%)</td><td valign="top" align="center" rowspan="1" colspan="1">6 (6%)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">24-48 h</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;None</td><td valign="top" align="center" rowspan="1" colspan="1">72 (77%)</td><td valign="top" align="center" rowspan="1" colspan="1">83 (84%)</td><td valign="top" align="center" rowspan="4" colspan="1">0.606</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Mild</td><td valign="top" align="center" rowspan="1" colspan="1">13 (14%)</td><td valign="top" align="center" rowspan="1" colspan="1">5 (5%)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Moderate</td><td valign="top" align="center" rowspan="1" colspan="1">4 (4%)</td><td valign="top" align="center" rowspan="1" colspan="1">6 (6%)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Severe</td><td valign="top" align="center" rowspan="1" colspan="1">5 (5%)</td><td valign="top" align="center" rowspan="1" colspan="1">5 (5%)</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>Data are presented as number of patients (percentage). D group: 5 mg of dexamethasone with normal saline IV, PD group: 0.075 mg of palonosetron plus 5 mg of dexamethasone IV.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4</label><caption><title>Incidence of Adverse Events and Patient Satisfaction during the First 48 Hours after Surgery</title></caption><alternatives><graphic xlink:href="kjae-68-267-i004"/><table frame="hsides" rules="rows"><thead><tr><th valign="middle" align="center" rowspan="1" colspan="1"/><th valign="middle" align="center" rowspan="1" colspan="1">D group (n = 94)</th><th valign="middle" align="center" rowspan="1" colspan="1">PD group (n = 99)</th><th valign="middle" align="center" rowspan="1" colspan="1">P values</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Adverse effect</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Dizziness</td><td valign="top" align="center" rowspan="1" colspan="1">17 (18%)</td><td valign="top" align="center" rowspan="1" colspan="1">19 (19%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.844</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Headache</td><td valign="top" align="center" rowspan="1" colspan="1">10 (11%)</td><td valign="top" align="center" rowspan="1" colspan="1">20 (20%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.067</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Satisfaction</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Satisfied</td><td valign="top" align="center" rowspan="1" colspan="1">77 (82%)</td><td valign="top" align="center" rowspan="1" colspan="1">80 (81%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.873</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Neutral</td><td valign="top" align="center" rowspan="1" colspan="1">11 (12%)</td><td valign="top" align="center" rowspan="1" colspan="1">15 (15%)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Dissatisfied</td><td valign="top" align="center" rowspan="1" colspan="1">6 (6%)</td><td valign="top" align="center" rowspan="1" colspan="1">4 (4%)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn><p>Data are presented as number of patients (percentage). D group: 5 mg of dexamethasone with normal saline IV, PD group: 0.075 mg of palonosetron plus 5 mg of dexamethasone IV.</p></fn></table-wrap-foot></table-wrap></floats-group></article>